Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2SDM0
|
|||
| Drug Name |
SLN360
|
|||
| Drug Type |
RNA interference
|
|||
| Indication | Hyperlipidemia [ICD-11: 5C80.Z] | Phase 2 | [1] | |
| Company |
Silence Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Apolipoprotein A messenger RNA (LPA mRNA) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Plasminogen activating cascade | |||
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | LDL-mediated lipid transport | |||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05537571) A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events. U.S.National Institutes of Health. | |||
| REF 2 | Recent lipoprotein(a) trials. Curr Opin Lipidol. 2022 Dec 1;33(6):301-308. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.